Please provide your email address to receive an email when new articles are posted on . Sixty-six adults with binge-eating disorder were given either naltrexone/bupropion or placebo for 16 weeks. The combination of naltrexone and bupropion results in a response rate almost six times greater than with placebo in patients with moderate or severe methamphetamine use disorder, results of a new ...

Context Explanation

Nasdaq: NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine FiercePharma: Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union Contrave (naltrexone/bupropion) is a prescription drug used for weight loss and long-term weight management in certain adults. The drug is prescribed along with diet ... DUBLIN, Jan. 14, 2021 /PRNewswire/ -- Results from a National Institute on Drug Abuse (NIDA)-funded study evaluating the efficacy and safety of naltrexone for extended-release injectable suspension ...

Insight Material